Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06168201 · ClinicalTrials.gov registry record
VIrtual STudy in Achondroplasia for the US (VISTA)
A clinical trial of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- 170
- Enrollment target
- 7
- Study locations
NCT06168201: Recruiting study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
NCT06168201 is a study of Achondroplasia that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 170 participants, above the 132-participant average among 9 other Achondroplasia trials with a reported enrollment target (29% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06168201, a study of Achondroplasia, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- 170 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an observational study of individuals with achondroplasia in the United States. The primary study population consists of pediatric individuals treated and untreated with VOXZOGO™. Study enrollment started in February 2023. The projected total duration of the study is approximately 5 years at minimum from start of study recruitment in February 2023, with the duration of individual prospective follow-up differing depending on the time of enrollment. The study duration may be extended based on decisions by the study sponsor. Data will be collected in two formats for the primary pediatric study population: 1. Participant-mediated access to electronic health records(including medical imaging, when available) which will enable retrospective and prospective collection of secondary data reflecting real-life treatment use and clinical care. . 2. Primary data collection of Clinical Outcome Assessments (COAs) and questionnaire data. Data will be collected in the following format for the adult cohort: \- Participant-mediated access to electronic health records (including medical imaging, when available) which will enable retrospective and prospective collection of secondary data reflecting real-life treatment use and clinical care. The primary study population will include approximately 150 pediatric individuals with achondroplasia regardless of their treatment status with VOXZOGO™. Individuals may change status from untreated to treated during the prospective period of the study (or vice versa) however they will only be counted once, based on their treated status at the point of enrollment. The secondary study population will include 20 adolescent and adult participants.
Primary Outcome
sitting and standing measured in centimetres
Conditions Studied
Study Locations (7)
California
- UCSF - Oakland
- PicnicHealth - San Francisco
North Carolina
- Piedmont Health - Statesville
Ohio
- University of Cincinnati - Cincinnati
South Dakota
- Sanford Health - Sioux Falls
Texas
- Baylor College of Medicine - Houston
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2028-02 |
What NCT06168201 shows while recruiting
NCT06168201 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 9 other Achondroplasia trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT06168201 lists 7 locations in 6 states (California, North Carolina, Ohio).
Frequently Asked Questions
What is clinical trial NCT06168201 about?
NCT06168201 is a clinical study titled "VIrtual STudy in Achondroplasia for the US (VISTA)". This is an observational study of individuals with achondroplasia in the United States. The primary study population consists of pediatric individuals treated and untreated with VOXZOGO™. Study enrollment started in February 2023. The projected total duration of the study is approximately 5 years at...
What is the current status of trial NCT06168201?
This trial is currently recruiting. The enrollment target is 170 participants. The study started on 2023-02-21. Estimated completion is 2028-02.
What conditions does trial NCT06168201 study?
This clinical trial studies the following conditions: Achondroplasia.
Who is sponsoring clinical trial NCT06168201?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06168201 being conducted?
This trial has 7 study locations across California, North Carolina, Ohio, South Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06168201's enrollment target sits among peer trials
170 3rd of 9 higher than 7 of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI